Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Cellectis SA ( (CLLS) ) has issued an update.
Cellectis S.A. released its interim financial report for the six-month period ending June 30, 2025, showcasing its financial position and performance. The report highlights a significant increase in non-current financial assets and other non-current assets, reflecting the company’s strategic investments and growth. This financial update provides stakeholders with insights into Cellectis’s operational progress and its positioning within the biotechnology industry.
The most recent analyst rating on (CLLS) stock is a Buy with a $7.00 price target. To see the full list of analyst forecasts on Cellectis SA stock, see the CLLS Stock Forecast page.
Spark’s Take on CLLS Stock
According to Spark, TipRanks’ AI Analyst, CLLS is a Neutral.
Cellectis SA’s stock score is primarily driven by its strong technical performance, reflecting current market optimism and momentum. Despite this, the company’s financial performance is hampered by profitability challenges, and the valuation presents significant risks due to ongoing losses. The absence of earnings call insights and corporate events means these factors did not influence the score.
To see Spark’s full report on CLLS stock, click here.
More about Cellectis SA
Cellectis S.A. is a biotechnology company based in Paris, France, specializing in gene-editing technologies. The company focuses on developing innovative therapies for various diseases, utilizing its proprietary TALEN technology to create precise genetic modifications.
Average Trading Volume: 134,016
Technical Sentiment Signal: Buy
Current Market Cap: $207.8M
For detailed information about CLLS stock, go to TipRanks’ Stock Analysis page.